Bluebird Bio announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher, or PRV, for $102M. Bluebird was granted two PRVs upon the FDA approvals of Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona for the treatment of early, active cerebral adrenoleukodystrophy, on August 17 and September 16 respectively. Bluebird will receive a payment of $102M upon closing of the transaction, which remains subject to customary closing conditions, including anti-trust review. The company continues to explore additional financing opportunities, including the monetization of its second PRV, and anticipates providing full year 2023 guidance early next year.
Published first on TheFly